Why diagnostic companies need to control their own market.
It has been nearly 20 years since what most consider to be the advent of Precision Medicine, when two targeted therapies (Herceptin and Gleevec) were first approved to treat narrowly defined groups of patients based on specific mutations in their disease. At that moment, diagnostics, which had previously been seen as valuable, but not always critical information in medical decision making, rose in their importance. Unfortunately, in the intervening 20 years, far less progress has been made in the use of diagnostics than would have been expected back in 1998. Across all
disease areas, most physicians continue to practice trial-and-error medicine, despite more and more data being available to guide treatment decisions.